0948 GMT - Novo Nordisk's launch of its Wegovy pill in the UAE is an important milestone as the company takes its first step outside the U.S. with an oral version of its obesity treatment, says AJ Bell's Russ Mould. "A pill version is expected to broaden the market for Wegovy given the logistical advantages--it does not require cold-chain refrigeration like liquid injection pens--and the fact that some people would be more comfortable with a pill than a jab." This is in evidence in the U.S., where a pill was launched at the start of this year and has already seen healthy demand, Mould says. Novo Nordisk's main rival, Eli Lilly, announced the launch of its own pill in the UAE in April. Shares rise 0.1%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

June 03, 2026 05:48 ET (09:48 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.